• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Efficacy of mogamulizumab in mycosis fungoides by patient blood involvement and time to response analysis in mycosis fungoides and Sézary syndrome: a post hoc analysis of the MAVORIC study.

作者信息

Beylot-Barry Marie, Booken Nina, Weishaupt Carsten, Medley Michael, Sun Wei, Rosen Jan-Paul

机构信息

Univ. Bordeaux, INSERM, BaRITOn, U1053, Bordeaux, France; Department of Dermatology, CHU Bordeaux, Bordeaux, France.

Department of Dermatology and Venereology, University Hospital Hamburg-Eppendorf, Hamburg, Germany.

出版信息

Eur J Cancer. 2021 Oct;156 Suppl 1:S47-S48. doi: 10.1016/S0959-8049(21)00714-0.

DOI:10.1016/S0959-8049(21)00714-0
PMID:34649657
Abstract
摘要

相似文献

1
Efficacy of mogamulizumab in mycosis fungoides by patient blood involvement and time to response analysis in mycosis fungoides and Sézary syndrome: a post hoc analysis of the MAVORIC study.通过蕈样肉芽肿患者血液受累情况及蕈样肉芽肿和塞扎里综合征的缓解时间分析评估莫加莫珠单抗治疗蕈样肉芽肿的疗效：MAVORIC研究的事后分析
Eur J Cancer. 2021 Oct;156 Suppl 1:S47-S48. doi: 10.1016/S0959-8049(21)00714-0.
2
Impact of blood involvement on efficacy and time to response with mogamulizumab in mycosis fungoides and Sézary syndrome.莫格利珠单抗治疗蕈样肉芽肿和塞扎里综合征时血液受累对疗效和反应时间的影响。
J Eur Acad Dermatol Venereol. 2023 Feb;37(2):311-316. doi: 10.1111/jdv.18549. Epub 2022 Aug 30.
3
Spotlight on Mogamulizumab-Kpkc for Use in Adults with Relapsed or Refractory Mycosis Fungoides or Sézary Syndrome: Efficacy, Safety, and Patient Selection.聚焦莫格利珠单抗 - Kpkc 在成人复发或难治性蕈样真菌病或塞扎里综合征中的应用：疗效、安全性和患者选择。
Drug Des Devel Ther. 2020 Sep 16;14:3747-3754. doi: 10.2147/DDDT.S185896. eCollection 2020.
4
Patient characteristics of long-term responders to mogamulizumab: results from the MAVORIC study.莫格利珠单抗长期缓解者的患者特征：MAVORIC研究结果
Eur J Cancer. 2021 Oct;156 Suppl 1:S48-S49. doi: 10.1016/S0959-8049(21)00715-2.
5
Understanding relative survival outcomes for patients with cutaneous T-cell lymphoma (CTCL) subtypes mycosis fungoides and Sézary syndrome treated with mogamulizumab or vorinostat: combining Australian real-world evidence and MAVORIC phase 3 trial data.了解接受莫加莫拉单抗或伏立诺他治疗的蕈样肉芽肿和 Sézary 综合征这两种皮肤 T 细胞淋巴瘤（CTCL）亚型患者的相对生存结果：结合澳大利亚真实世界证据和 MAVORIC 3 期试验数据。
Eur J Cancer. 2021 Oct;156 Suppl 1:S18. doi: 10.1016/S0959-8049(21)00659-6.
6
Mogamulizumab in the treatment of advanced mycosis fungoides and Sézary syndrome: safety and efficacy.莫格利珠单抗治疗晚期蕈样霉菌病和赛泽里综合征：安全性和疗效。
Expert Rev Anticancer Ther. 2020 Jun;20(6):447-452. doi: 10.1080/14737140.2020.1760096. Epub 2020 Apr 28.
7
Adjusting for treatment crossover in the MAVORIC trial: survival in advanced mycosis fungoides and Sézary syndrome.MAVORIC 试验中调整治疗交叉：晚期蕈样真菌病和塞扎里综合征的生存情况。
J Comp Eff Res. 2022 Aug;11(11):805-813. doi: 10.2217/cer-2022-0070. Epub 2022 Jun 9.
8
Efficacy and safety of mogamulizumab by patient baseline blood tumour burden: a post hoc analysis of the MAVORIC trial.基于患者基线血液肿瘤负担的莫格利珠单抗疗效和安全性：MAVORIC 试验的事后分析。
J Eur Acad Dermatol Venereol. 2021 Nov;35(11):2225-2238. doi: 10.1111/jdv.17523. Epub 2021 Aug 20.
9
Clinical characteristics and outcomes of black patients with mycosis fungoides and Sézary syndrome: a subgroup analysis of the phase III MAVORIC trial.蕈样肉芽肿和赛泽里综合征黑人患者的临床特征和结局：III 期 MAVORIC 试验的亚组分析。
Leuk Lymphoma. 2021 Aug;62(8):1877-1883. doi: 10.1080/10428194.2021.1888376. Epub 2021 Feb 22.
10
Lack of impact of type and extent of prior therapy on outcomes of mogamulizumab therapy in patients with cutaneous T cell lymphoma in the MAVORIC trial.MAVORIC 试验中，既往治疗的类型和范围对皮肤 T 细胞淋巴瘤患者 mogamulizumab 治疗结局无影响。
Leuk Lymphoma. 2021 Dec;62(13):3109-3118. doi: 10.1080/10428194.2021.1953007. Epub 2021 Jul 26.

引用本文的文献

1
[New treatment concepts and combination therapies for cutaneous T-cell lymphomas].[皮肤T细胞淋巴瘤的新治疗理念与联合疗法]
Dermatologie (Heidelb). 2022 Oct;73(10):782-787. doi: 10.1007/s00105-022-05053-x. Epub 2022 Sep 8.